NBIX
Neurocrine Biosciences·NASDAQ
--
--(--)
--
--(--)
NBIX fundamentals
Neurocrine Biosciences (NBIX) released its earnings on Feb 11, 2026: revenue was 805.50M (YoY +28.33%), beat estimates; EPS was 1.48 (YoY +48.00%), missed estimates.
Revenue / YoY
805.50M
+28.33%
EPS / YoY
1.48
+48.00%
Report date
Feb 11, 2026
NBIX Earnings Call Summary for Q4,2025
- Revenue Growth: 2025 total sales $2.8B (+22% YoY), INGREZZA $2.5B (+9% YoY), CRENESSITY $300M. 2026 INGREZZA guidance $2.7B-$2.8B (+10%).
- Pipeline Momentum: Phase III data for osavampator (MDD) and direclidine (schizophrenia) expected in 2027. NBI-890 VMAT2 inhibitor Phase II initiated.
- CRENESSITY Expansion: 2026 sales force expansion and AI-driven targeting to reach 10%+ patient penetration. Pediatric study for <4 years old patients underway.
- Financial Strength: $2.5B cash, 30% non-GAAP margin, and $850M operating income in 2025. 2026 R&D expenses to grow with pipeline advancement.
EPS
Actual | 0.39 | 0.81 | -0.62 | 3.58 | 0.33 | 0.43 | 0.23 | -0.08 | 0.14 | -0.18 | 0.69 | 0.88 | -0.79 | 0.95 | 0.82 | 1.44 | 0.42 | 0.63 | 1.24 | 1 | 0.08 | 1.06 | 2.04 | 1.48 | ||||||||||
Forecast | 0.5212 | 0.6613 | -0.0194 | 0.6014 | 0.5276 | 0.5019 | 0.5568 | 0.6775 | 0.3468 | 0.6088 | 0.8095 | 1.1199 | 0.6169 | 0.8146 | 1.0394 | 1.212 | 1.0981 | 1.1283 | 1.4926 | 1.6058 | 0.5352 | 0.9646 | 1.5944 | 1.8043 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -25.17% | +22.49% | -3095.88% | +495.28% | -37.45% | -14.33% | -58.69% | -111.81% | -59.63% | -129.57% | -14.76% | -21.42% | -228.06% | +16.62% | -21.11% | +18.81% | -61.75% | -44.16% | -16.92% | -37.73% | -85.05% | +9.89% | +27.95% | -17.97% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 237.10M | 302.40M | 258.50M | 247.90M | 236.60M | 288.90M | 296.00M | 312.00M | 310.60M | 378.20M | 387.90M | 412.00M | 420.40M | 452.70M | 498.80M | 515.20M | 515.30M | 590.20M | 622.10M | 627.70M | 572.60M | 687.50M | 794.90M | 805.50M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 226.53M | 261.31M | 282.70M | 260.45M | 250.67M | 273.19M | 297.83M | 317.49M | 304.07M | 342.33M | 377.00M | 408.87M | 410.66M | 447.34M | 479.09M | 518.52M | 512.40M | 545.98M | 600.64M | 629.46M | 559.63M | 653.88M | 746.85M | 790.50M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +4.66% | +15.72% | -8.56% | -4.82% | -5.61% | +5.75% | -0.61% | -1.73% | +2.15% | +10.48% | +2.89% | +0.77% | +2.37% | +1.20% | +4.12% | -0.64% | +0.57% | +8.10% | +3.57% | -0.28% | +2.32% | +5.14% | +6.43% | +1.90% |
Earnings Call
You can ask Aime
What factors drove the changes in Neurocrine Biosciences's revenue and profit?What is Neurocrine Biosciences's gross profit margin?What does Neurocrine Biosciences do and what are its main business segments?Did Neurocrine Biosciences beat or miss consensus estimates last quarter?What is Neurocrine Biosciences's latest dividend and current dividend yield?What is the market's earnings forecast for Neurocrine Biosciences next quarter?What is the revenue and EPS growth rate for Neurocrine Biosciences year over year?What were the key takeaways from Neurocrine Biosciences's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
